Sign in →

Test Code HYPOGM Hypoglycemic Agent Screen, Serum

Additional Codes

EPIC EAP  Mayo
LAB5316 HYPOG

Reporting Name

Hypoglycemic Agent Screen, S

Useful For

Evaluation of suspected insulinoma characterized by hypoglycemia and increased serum insulin concentration

 

Detecting the following drugs that stimulate insulin secretion:

-First-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)

-Second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)

-Meglitinides: repaglinide (Prandin) and nateglinide (Starlix)

-Thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)

 

This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Patient Preparation: Specimen must be collected during an episode of hypoglycemia.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume:1.5 mL Serum

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

Serum: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 28 days
  Refrigerated  28 days
  Ambient  7 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Day(s) Performed

Monday, Wednesday, Friday

CPT Code Information

G0480
80377 (if appropriate for select payers)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HYPOG Hypoglycemic Agent Screen, S 68318-5

 

Result ID Test Result Name Result LOINC Value
21295 Chlorpropamide 48329-7
21298 Glimepiride 48325-5
21299 Glipizide 48326-3
21300 Glyburide 48327-1
609767 Nateglinide 49487-2
609768 Pioglitazone 100351-6
21301 Repaglinide 48328-9
609769 Rosiglitazone 100352-4
21296 Tolazamide 21566-5
21297 Tolbutamide 21567-3

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Report Available

2 to 6 days

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.